Clinical remission

When your symptoms have settled, judged by a symptom score or how you feel. It does not always mean the inflammation inside the bowel has gone.

Also called: symptom remission, in remission, symptom free

Related words endoscopic remission deep remission steroid-free remission remission

Topics Research Flare-ups

Questions people ask

What do 'flare-up' and 'remission' mean?

Crohn's usually comes and goes. Crohn's & Colitis UK describes remission as a time when Crohn's is well controlled, you feel better and tests show less inflammation, although some symptoms like tiredness may linger. A flare-up (also called a relapse or active disease) is when symptoms return and tests show the gut is inflamed. The NHS says a flare can last from a few days to several months.

Sources

What is the CDAI, and how is it different from the HBI?

The Crohn's Disease Activity Index (CDAI) is an older, longer score. It needs a 7-day symptom diary, your weight and a blood test result, so it takes more effort to work out. A CDAI under 150 is taken as a marker of remission and over 450 as a marker of severe Crohn's. The Harvey-Bradshaw Index is a simpler score based on just the previous day's symptoms and does not need a blood test.

Sources

Why am I so tired all the time with Crohn's?

Fatigue is one of the commonest Crohn's symptoms. Crohn's & Colitis UK says it affects around 7 in 10 people during a flare and around 4 in 10 in remission, and has many possible causes. Anaemia from blood loss or poor absorption is one of them, so a blood test is worth asking about. A Cochrane review found only weak evidence so far for specific fatigue treatments.

Sources

How can I take part in a Crohn's clinical trial?

The NHS suggests asking your doctor or a patient organisation about trials you may be eligible for. You can also search the NIHR's Be Part of Research website for UK studies and contact research teams directly. Registries such as ISRCTN and ClinicalTrials.gov list studies and their results. Crohn's & Colitis UK explains how new medicines are tested before they are licensed.

Sources

What is the difference between 'step-up' and 'top-down' treatment?

Step-up means starting with simpler treatments such as steroids and only moving on to stronger medicines if those do not work. Top-down means starting a biologic early, usually infliximab together with an immunomodulator. The UK PROFILE trial found that, in newly diagnosed people with active Crohn's, top-down treatment led to far more steroid-free and surgery-free remission after a year, and fewer hospital stays and complications after five years. The 2025 BSG guideline now suggests early infliximab for moderate to severe Crohn's.

Sources

Where to read more

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD)

Gastroenterology Guideline Apr 2021 For professionals

An international expert agreement on what 'treat to target' should aim for in IBD. Short-term goals are feeling better and getting blood and poo inflammation tests back to normal. Long-term goals include a healed bowel lining seen at endoscopy, no disability, a normal quality of life, and normal growth in children. Healing through the full bowel wall in Crohn's is not yet a formal target but is a sign of deeper remission.

Topics Monitoring Research Medicines

Jargon explained treat to target endoscopic healing transmural healing biomarker calprotectin CRP clinical remission

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

Gastroenterology Study Jan 2007 Patients and professionals

The main trial behind adalimumab (Humira and its biosimilars) for keeping Crohn's under control. People who improved on adalimumab were much more likely to still be in remission at about a year if they kept taking it (36-41%) than if switched to placebo (12%). Taking it weekly worked no better than every other week.

Topics Biologics and newer medicines

Jargon explained maintenance remission CDAI placebo

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children (REACH)

Gastroenterology Study Mar 2007 Patients and professionals

The key trial of infliximab in 112 children with moderate to severe Crohn's. After the first three doses, 88% had improved and 59% were in remission. Children given the drug every 8 weeks afterwards did better at one year than those given it every 12 weeks. It led to infliximab being used for children.

Topics Children and young people Biologics and newer medicines

Jargon explained induction maintenance clinical response PCDAI

Crohn's disease

NHS inform (Scotland) Web page For patients

Scotland's national health information page on Crohn's. It explains that inflammation can occur anywhere from mouth to back passage but is most common in the last part of the small intestine or the colon, that it is usually diagnosed between 15 and 40, and lists common and less common symptoms, remission and flare-ups.

Topics About Crohn's disease Symptoms

Jargon explained ileum colon remission flare-up

Diets for inducing and maintaining remission in inflammatory bowel disease (IBD)

Cochrane Systematic review Feb 2019 Patients and professionals

A Cochrane review of 18 trials that tested cutting down or cutting out foods thought to provoke IBD symptoms. The authors found the evidence too weak to say whether any of these diets help bring on or keep remission, and called for better trials. This summary dates from 2019.

Topics Diet and nutrition Research

Jargon explained remission exclusion diet randomised controlled trial

British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025

British Society of Gastroenterology Guideline Jun 2025 For professionals

The current UK specialist guideline for managing IBD in adults, replacing the 2019 version. It is designed to sit alongside the IBD Standards and encourage use of the national primary care pathway for lower gut symptoms so diagnosis is quicker and more accurate. Among its general principles, it recommends classifying Crohn's using the Montreal system.

Topics About Crohn's disease Diagnosis and tests Medicines Monitoring Complications Surgery

Jargon explained Montreal classification remission endoscopic remission inflammatory bowel disease advanced therapy GRADE induction maintenance

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease (FORTIFY)

The Lancet Study May 2022 For professionals

The main international trial of risankizumab injections to keep Crohn's under control after a good response to drip treatment. More people who stayed on risankizumab remained in remission and had gut healing than those switched to placebo, and side effects were similar between groups.

Topics Biologics and newer medicines Research

Jargon explained IL-23 maintenance placebo endoscopic response

A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE)

The Lancet Gastroenterology & Hepatology Study May 2024 Patients and professionals

A large UK-led trial of 386 newly diagnosed adults. Starting straight away with infliximab plus an immunosuppressant ('top-down') kept 79% in remission without steroids or surgery for a year, compared with 15% using the usual 'step-up' approach of trying milder drugs first. There were also fewer flares, serious side effects and operations. A blood test meant to predict who needed strong treatment did not help. Free to read in full.

Topics Biologics and newer medicines Research About Crohn's disease

Jargon explained top-down treatment step-up treatment biomarker steroid-free remission top-down step-up immunomodulator randomised controlled trial

Search everything for "clinical remission"